Riskpilot← Back to searchSign inGet full accessCelemedic AB
ABActiveOrg 5591745509Gamla Grycksbovägen 44Hospital activities · NACE 8610Est. 20181 employees
Revenue 2025
SEK 826K
+16% vs 2024
EBITDA margin
84.8%
+23% vs 2024
Equity ratio
71.6%
Financial strength
Net profit 2025
SEK 558K
+17% vs 2024
| Revenue | SEK 826K | +16% |
| EBITDA | SEK 701K | +23% |
| Net profit | SEK 558K | +17% |
| Total assets | SEK 1,2M | +17% |
| Equity | SEK 880K | +41% |
| Employees | 1 | — |
Legal name
Celemedic AB
Org number
5591745509
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
9 oktober 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva medicinska konsultationstjänster i öppen- och slutenvård, äga och förvalta värdepapper och kapital samt bedriva därmed förenliga verksamheter.
Address
Gamla Grycksbovägen 44
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 117 | 93 | 521 | 710 | 826 |
| Staff expenses | — | −2 | −14 | −13 | −6 |
| EBITDA | 111 | 86 | 460 | 570 | 701 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 111 | 86 | 460 | 570 | 701 |
| Net financials | — | −0 | 4 | 16 | 2 |
| Profit before tax | 111 | 86 | 463 | 603 | 703 |
| Tax | −15 | −26 | −96 | −124 | −145 |
| Net profit | 96 | 60 | 368 | 478 | 558 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 283 | 344 | 729 | 1 051 | 1 230 |
| Equity | 217 | 276 | 444 | 623 | 880 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 49 | 51 | 268 | 428 | 350 |
| Total debt | 49 | 51 | 268 | 428 | 350 |
EBITDA margin
84.8%
This company
15.8%
Market median
+437% vs market
20212025
Equity ratio
71.6%
This company
38.2%
Market median
+87% vs market
20212025
Return on equity
63.4%
This company
18.4%
Market median
+245% vs market
20212025
Net profit margin
67.5%
This company
8.1%
Market median
+733% vs market
20212025
Asset turnover
0.67×
This company
1.12×
Market median
-40% vs market
20212025
Debt / equity
0.40×
This company
0.62×
Market median
+35% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PS Chief Executive Officer | Chief Executive Officer | 2022 |
JE Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Celemedic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Patrik Sune Andreas Söderberg | Chief Executive Officer | 0 companies |
| Julia Emily Söderberg | Deputy Chief Executive Officer | 0 companies |